Tokai Pharmaceuticals, Inc. (NASDAQ:TKAI) [Trend Analysis] try to make new thrust in street and making different trends, stocks trading ended with 25.49% to $1.28. Scott + Scott, Attorneys at Law, LLP, a global investor rights law firm, reminds investors that September 30, 2016 is the last day to file lead plaintiff papers in the securities court case against Tokai Pharmaceuticals, Inc. (TKAI). The Complaint alleges that all through the Class Period, Defendants made materially false and misleading statements regarding Tokai’s business, operational and compliance policies.
Particularly, Defendants made false and/or misleading statements and/or failed to disclose that: (1) there were noteworthy structural problems with ARMOR3-SV, the trial design for Tokai’s pivotal Phase 3 Galeterone study, (2) accordingly, ARMOR3-SV would probably not meet its primary endpoint; (3) therefore, the likelihood of Galeterone’s commercialization was not as probable as Tokai had told investors; and (4) consequently, Tokai’s financial statements, and Defendants’ statements regarding Tokai’s business, operations, and prospects, were false and misleading and/or lacked a reasonable basis. The share price of TKAI attracts active investors, as stock price of week volatility recorded 11.80%. The stock is going forward to its 52-week low with 30.61% and lagging behind from its 52-week high price with -91%.
Sequans Communications S.A. (NYSE:SQNS) [Trend Analysis] moved down reacts as active mover, shares a decrease -10% to traded at $1.71 and the percentage gap among open changing to regular change was -15.79%. Sequans Communications S.A. (SQNS) reported that pricing of an underwritten public offering of American Depositary Shares (ADSs), representing 15,151,520 ordinary shares, at a price of $1.65 per ADS, in an underwritten public offering under an effective shelf registration statement filed with the Securities and Exchange Commission.
The Firm has also granted to the underwriters a 30-day option to takeover an additional 2,272,728 ADSs to cover overallotments, if any, in connection with the Offering. Following the underwriting discount and estimated offering expenses payable by the Firm, the Firm expects to receive net proceeds of about $22.9 million, assuming no exercise of the overallotment option. The Firm intends to use the net proceeds from the Offering for general corporate purposes. The Offering is predictable to close on September 20, 2016, subject to customary closing conditions. The firm’s current ratio calculated as 1.20 for the most recent quarter. The firm past twelve months price to sales ratio was 2.83 and price to cash ratio remained 15.08.
Amphenol Corporation (NYSE:APH) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it 1.63% to close at $62.79 with the total traded volume of 1.14 Million shares. Its price to sales ratio ended at 3.38. APH attains analyst recommendation of 2.40 with week performance of 0.06%.